

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Cuttitta *et al.*

Application No. 10/529,118

Filed: March 24, 2005

Confirmation No. 6689

FILED VIA EFS

For: VASOREGULATING COMPOUNDS AND
METHODS OF THEIR USE

Examiner: Dameron Levest Jones

Art Unit: 1618

Attorney Reference No. 4239-66904-02

COMMISSIONER FOR PATENTS
SUBMITTED VIA ELECTRONIC FILING SYSTEM

INFORMATION DISCLOSURE STATEMENT PURSUANT TO
37 C.F.R. § 1.97(d)

Listed on the accompanying form PTO-1449 and submitted herewith is one English-language publication and a European Supplemental Search Report from a corresponding pending European application. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement (IDS) is being filed after the date of either a final action or, a notice of allowance, and before payment of the issue fee.

This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned hereby certifies that each item of information contained in the IDS filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the IDS.

Submitted herewith, via EFS, the fee (\$180.00) as required by 37 C.F.R. § 1.97(d) and as set forth in 37 C.F.R. § 1.17(p). Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630

cc: Docketing